Body-on-a-Chip

Auteur
Anthony Atala, MD, is the G. Link Professor and Director of the Wake Forest Institute for Regenerative Medicine, and the W. Boyce Professor and Chair of Urology. Dr. Atala is a practicing surgeon and a researcher in the area of regenerative medicine. Fifteen applications of technologies developed in Dr. Atala's laboratory have been used clinically. He is Editor of 25 books and 3 journals. Dr. Atala has published over 800 journal articles and has received over 250 national and international patents. Dr. Atala was elected to the Institute of Medicine of the National Academies of Sciences, to the National Academy of Inventors as a Charter Fellow, and to the American Institute for Medical and Biological Engineering.

Dr. Atala has led or served several national professional and government committees, including the National Institutes of Health working group on Cells and Developmental Biology, the National Institutes of Health Bioengineering Consortium, and the National Cancer Institute's Advisory Board. He is a founding member of the Tissue Engineering Society, Regenerative Medicine Foundation, Regenerative Medicine Manufacturing Innovation Consortium, Regenerative Medicine Development Organization, and Regenerative Medicine Manufacturing Society. Dr. Zhang's research interests include 3D bioprinting, organ-on-a-chip, biomaterials, regenerative engineering, and bioanalysis. His scientific contributions have been recognized by over 40 regional, national, and international awards. He has been invited to deliver more than 170 lectures worldwide and has served as reviewer for more than 700 manuscripts for as many as 60 journals. He is serving as Editor-in-Chief for Microphysiological Systems and is Associate Editor for Bio-Design and Manufacturing, Nano Select, Aggregate, Nano TransMed, and Essays in Biochemistry. He is also on the Editorial Board of Biofabrication, Bioprinting, Advanced Healthcare Materials, Regenerative Biomaterials, Discover Materials, BMC Biomedical Engineering, Materials Today Bio, Bioengineering, Pharmaceutics, Materials Futures, Biomedical Engineering and Computational Biology, International Journal of Bioprinting, and Chinese Chemical Letters, Editorial Advisory Board of Biomicrofluidics, International Advisory Board of Advanced NanoBiomed Research and Advanced Materials Technologies, and Advisory Panel of Nanotechnology. At leisure (if any), Dr. Zhang enjoys bird- and nature-watching, traveling, photography, and technology

Texte du rabat
Body-on-a-chip (BOC) systems consists of multiple microscale models of different human organ (physiologically scaled to one another) that are physically connected located on a synthetic "chip? format and connected to each other using a microfluidic system, thus emulating the circulatory system within the body. Simpler versions of these systems, known as Organ-on-a-chip (OOC) consists of one organ per chip and have been an emerging area of interest since the past 13-15 years as in vitro biomimetic systems for predicting physiological response to drugs and chemicals. Although animal models have been the gold standards for preclinical drug testing, animal models often do not predict human response effectively; thus, increasing the demand for more advanced in vitro human tissue/ organ model platforms. Since, BOC systems can recapitulate native tissue/ organ architecture, diffusion kinetics of drugs physiological flow conditions etc., similar to what would happen in the body, they are particularly powerful in predicting human efficacy prior to clinical testing of a drug, determining potential toxicity, or in clinical studies to test underlying mechanisms or action or adverse effects. With recent advancements in high-throughput analysis systems and artificial intelligence, it has also become possible to screen several drugs at a time, thus significantly speeding up discovery, development and testing of pharmacologically useful compounds and reducing costs. Now BOC systems are also finding applications in evaluating the safety of chemicals, cosmetics, food ingredients, and also in life science research. Body-on-a-chip: Essentials and Applications provides the reader high quality information, in a single resource, necessary to explore the use of BOC systems from design and development to testing and personalized medicine, to medical research and diagnostics.

Contenu

1. The Concept of Organ-on-a-Chip and Body-on-a-Chip Devices 2. Advances in Three-Dimensional Cell Culture 3. Organoids and Spheroids 4. Microfluidics 5. Materials for fabricating Micro-physiological Systems 6. Design and Engineering of Multi-organ Systems 7. Recent Trends in Microfluidic Platforms for Body-on-a-chip systems 8. Chapter Microfabrication Techniques for Making Organ-on-a-Chip and Body-on-a-Chip Devices 9. Combining 3D bioprinting with organ-on-a-chip technology 10. Incorporating Biological Components within Organ-on-a-Chip and Body-on-a-Chip Systems 11. On-chip Sensing and Data Analysis from Multi-organ Systems 12. Liver-on-a-chip 13. Lung-on-a-chip 14. Lung-on-a-chip As a Model for Studying Effects of Cigarette Smoke 15. Kidney-on-a-chip 16. Adrenals-on-a-Chip 17. Heart-on-a-chip 18. Pancreas-on-a-Chip 19. Spleen-on-a-Chip 20. Skin-on-a-Chip 21. Blood Vessels-on-a-Chip 22. Bone-on-a-Chip 23. Cartilage-on-a-Chip 24. Muscle-on-a-Chip 25. Bladder-on-a-Chip 26. Testis-on-a-Chip 27. Ovary-on-a-chip 28. Thyroid-on-a-Chip 29. Thymus-on-a-Chip 30. Brain-on-a-Chip 31. Salivary glands-on-a-Chip 32. Bone marrow on a Chip 33. Human Organ-on-a-Chip Models for Diseases 34. Cancer-on-a-Chip 35. Modeling Disease Pathogenesis Using Organ-on-a-chip Platforms 36. Organ-on-a-chip using stem cells 37. Role of Body-on-a-chip Technology in Drug Discovery and Development 38. Computational Pharmacokinetic Modeling of Body-on-chip Devices 39. Drug and Toxicity Screening Using Multi-organ Systems 40. Micro-physiological Systems for Screening Environmental Toxins and Pollutants 41. Challenges in Manufacturing and Commercial Use of Body-on-a-chip and other Micro-physiological Devices 42. Body-on-chip Devices and the Regulatory Agencies 43. Body-on-chip Systems and Clinical Biomarkers Discovery 44. Body-on-chip Systems and chemical agents 45. Body-on-chip Systems and viral agents 46. Body-on-chip Systems and omics 47. Body-on-chip Systems and artificial intelligence- pathways for the future